McGrath, C.

price health effectiveness disease innovation market technology cost-effectiveness development product study analysis value comparator research threshold disease area patient ied max investment result level disease areas drug development bene fits bene fit future period price erosion pricing system model ed max policy systolic blood pressure process management decision refoio camejo entrant pressure industry point refoios camejo treatment 12.5 cozaar blood funding ef ficiency molecule pd min hypertension 2.5 characteristic bendroflumeth competition subclasse erosion population decrease ficient increase systolic study period subclas institute framework signi cohort entry date effect /qaly p /pack table place society costeffectivenes number antihypertensive drugs